Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma

Table 1

Patients and administered drugs.

Patient; number	Age	Gender	Drug^a and dose	Drug^b substance	Time period after last administration	Coadministered drug	Coadministered drug substance and dose
1	79	F	Co-Diovan; 160 mg/12,5 mg	VAL, HCT	8	Aricept	5 mg dorepezil HCl
2	52	F	Norvasc; 10 mg	AML	12	Mentopin; Micardis	200 mg acetylcysteine; 80 mg telmisartan
3	80	F	Norvasc; 10 mg	AML	6	Glukofen	850 mg metformin HCl
4	63	M	Exforge; 5/160 mg	AML, VAL	8	Ator	10 mg atorvastatin
5	71	F	Diovan; 160 mg	VAL	8	Apranax	275 mg naproxen sodium
6	65	M	Hipersar Plus; 20 mg/12.5 mg	OLM, HCT	7	Lipitor	20 mg atorvastatin
7	74	M	Sevikar HCT; 40 mg/10 mg/25 mg	OLM, AML, HCT	8.5	Pletal	10 mg cilestazol
8	56	F	Cardopan Plus; 80 mg/12.5 mg	VAL, HCT	24	Sirdalud	2 mg tizanidine

aDrugs that have been used for hypertension therapy.
^bThe active substances of the antihypertensive drugs.